Last reviewed 2026-04-23 · How we verify

naphazoline hydrocloride

EMS · Phase 3 active Small molecule

naphazoline hydrocloride is a Alpha-1 adrenergic agonist Small molecule drug developed by EMS. It is currently in Phase 3 development for Ocular redness and congestion associated with minor eye irritation, Nasal congestion due to allergies or colds.

Naphazoline hydrochloride is an alpha-1 adrenergic agonist that causes vasoconstriction of blood vessels in the eye or nasal passages.

Naphazoline hydrochloride is an alpha-1 adrenergic agonist that causes vasoconstriction of blood vessels in the eye or nasal passages. Used for Ocular redness and congestion associated with minor eye irritation, Nasal congestion due to allergies or colds.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	naphazoline hydrocloride
Sponsor	EMS
Drug class	Alpha-1 adrenergic agonist
Target	Alpha-1 adrenergic receptor
Modality	Small molecule
Therapeutic area	Ophthalmology / Otolaryngology
Phase	Phase 3

Mechanism of action

By stimulating alpha-1 adrenergic receptors on vascular smooth muscle, naphazoline induces rapid constriction of small blood vessels. This reduces blood flow to the affected tissue, decreasing congestion, redness, and swelling. The drug is commonly used as a topical decongestant in ophthalmic and nasal formulations.

Approved indications

Ocular redness and congestion associated with minor eye irritation
Nasal congestion due to allergies or colds

Common side effects

Ocular irritation or stinging
Rebound congestion (with prolonged nasal use)
Mydriasis (pupil dilation)
Headache

Key clinical trials

Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

naphazoline hydrocloride CI brief — competitive landscape report
naphazoline hydrocloride updates RSS · CI watch RSS
EMS portfolio CI

Frequently asked questions about naphazoline hydrocloride

What is naphazoline hydrocloride?

naphazoline hydrocloride is a Alpha-1 adrenergic agonist drug developed by EMS, indicated for Ocular redness and congestion associated with minor eye irritation, Nasal congestion due to allergies or colds.

How does naphazoline hydrocloride work?

Naphazoline hydrochloride is an alpha-1 adrenergic agonist that causes vasoconstriction of blood vessels in the eye or nasal passages.

What is naphazoline hydrocloride used for?

naphazoline hydrocloride is indicated for Ocular redness and congestion associated with minor eye irritation, Nasal congestion due to allergies or colds.

Who makes naphazoline hydrocloride?

naphazoline hydrocloride is developed by EMS (see full EMS pipeline at /company/ems).

What drug class is naphazoline hydrocloride in?

naphazoline hydrocloride belongs to the Alpha-1 adrenergic agonist class. See all Alpha-1 adrenergic agonist drugs at /class/alpha-1-adrenergic-agonist.

What development phase is naphazoline hydrocloride in?

naphazoline hydrocloride is in Phase 3.

What are the side effects of naphazoline hydrocloride?

Common side effects of naphazoline hydrocloride include Ocular irritation or stinging, Rebound congestion (with prolonged nasal use), Mydriasis (pupil dilation), Headache.

What does naphazoline hydrocloride target?

naphazoline hydrocloride targets Alpha-1 adrenergic receptor and is a Alpha-1 adrenergic agonist.

Drug class: All Alpha-1 adrenergic agonist drugs
Target: All drugs targeting Alpha-1 adrenergic receptor
Manufacturer: EMS — full pipeline
Therapeutic area: All drugs in Ophthalmology / Otolaryngology
Indication: Drugs for Ocular redness and congestion associated with minor eye irritation
Indication: Drugs for Nasal congestion due to allergies or colds

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing